On January 5, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, reported that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET (Press release, Intellia Therapeutics, JAN 5, 2022, View Source [SID1234598305]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation.

On January 5, 2022 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported that senior leadership plans to present at the following conferences in January (Press release, Genocea Biosciences, JAN 5, 2022, View Source [SID1234598304]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conferences:

Event: Longwood Healthcare Leaders Winter Webconference – Details
Topic 1: Innovation in Cell Therapy
Format: Panel
Date: Thursday, January 6, 2022
Time: 1:30 PM ET
Topic 2: Making a Big Impact With Limited Resources
Format:
Date:
Time: Panel
Thursday, January 6, 2022
5:10 PM ET

Event:

LifeSci Partners 11th Annual Corporate Access Event – Details
Topic 1: Innovative Approaches to Cell Therapy for Oncology
Format: Panel
Date: Friday, January 7, 2022
Time: 8:30 AM ET
Topic 2: Cancer Vaccines: Promises, Promises … Has Their Day Come?
Format:
Date:
Time: Panel
Friday, January 7, 2022
2:00 PM ET

Event: H.C. Wainwright BIOCONNECT Virtual Conference – Details
Topic: Corporate Update
Format: On demand presentation
Date: Monday, January 10, 2022
Time: 7:00 AM ET

Event: Advanced Therapies Week – Details
Topic: Add It Up: 3 Things to Consider for Capacity Expansion
Format: Panel
Date: Wednesday, January 26, 2022
Time: 5:00 PM ET

On January 5, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a strategic restructuring (Press release, FierceBiotech, JAN 5, 2022, View Source [SID1234598303]). The company will prioritize its late-stage product opportunities, poziotinib and ROLONTIS (eflapegrastim), and will deprioritize development activities of its early-stage clinical development and research programs. The company has made these decisions following a detailed review of its operations, portfolio and growth opportunities, and will focus its resources accordingly.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The decision to restructure the organization is necessary to focus on our advanced clinical programs that will drive our future growth. I would like to express my appreciation to our colleagues who are affected by this decision and are leaving Spectrum. We are grateful for their dedication and their contributions to advancing our mission," said Tom Riga, President and Chief Executive Officer, Spectrum Pharmaceuticals. "The changes we are implementing are expected to result in a reduction in operating expenses and the extension of the company’s cash runway into 2023."

Spectrum intends to implement the following strategic restructuring initiatives to reduce its expenses and extend its existing cash runway:

Spectrum is prioritizing the development activities for its late-stage assets, poziotinib and ROLONTIS, and will deprioritize work on its early-stage pipeline, FIT Program (IGN 002) and IL-12.
The company restructuring will result in a workforce reduction of approximately 30%.
Operating cash burn is expected to be reduced by 20-25%, which should extend the cash runway into 2023.
The physical footprint of selected facilities will be significantly reduced in 2022.

On January 5, 2022 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, reported that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion (Press release, Thermo Fisher Scientific, JAN 5, 2022, View Source,-a-Leader-in-Recombinant-Proteins [SID1234598302]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech’s recombinant proteins portfolio complements Thermo Fisher’s cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.

"PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "In combination with our proprietary bioprocessing and cell culture technologies, this complementary transaction positions us to partner with our customers to drive the evolution of the fast-growing market for cell and gene therapies. By leveraging our commercial reach, we will be able to efficiently grow the PeproTech business and generate attractive financial results all while furthering our Mission to enable our customers to make the world healthier, cleaner and safer."

Casper added, "With more than three decades of experience across a broad range of applications for drug development and therapeutic products, the PeproTech team has built long-standing customer relationships in pharma and biotech and life sciences research. We look forward to welcoming their incredibly talented team to Thermo Fisher."

Bob Goldman, president and co-founder of PeproTech, commented, "We are pleased to join Thermo Fisher given their team’s outstanding industry leadership and shared commitment to develop innovative therapies that improve patient outcomes. PeproTech’s reputation for unparalleled product consistency and quality directly aligns with that of Thermo Fisher’s, and we look forward to building on our success as part of the world leader in serving science."

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

On January 5, 2022 Cyclenium Pharma, Inc. ("Cyclenium"), an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. ("Vuja De"), a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, reported the signing of a drug discovery collaboration agreement (Press release, Cyclenium, JAN 5, 2022, View Source [SID1234598300]). The companies will screen and optimize lead candidates to advance treatments uniquely suited for preventing cancer metastatic recurrence, the biggest unmet need in oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will exploit Vuja De’s proprietary anti-metastatic progression in vitro and ex vivo drug discovery screening platform and Cyclenium’s proprietary QUEST Library of next generation synthetic small-molecule macrocycles and associated optimization expertise to identify clinical candidates effective against dormant disseminated tumor cells for the prevention of metastatic cancer recurrence. Vuja De will be responsible for all screening efforts, while Cyclenium will be responsible for all medicinal chemistry efforts to generate new optimized macrocyclic compounds by employing its unique CMRT Technology.

"We are very excited about entering this collaboration with Vuja De," stated Helmut Thomas, Ph.D., President, Chief Executive Officer & Chief Scientific Officer of Cyclenium. "We are confident that our CMRT Technology and proven success in the macrocycle area combined with the innovative anti-metastatic progression platform and excellent research team at Vuja De will enable the discovery and development of novel macrocyclic therapeutic agents to effectively control metastatic progression."

"We highly appreciate Cyclenium’s expertise in the macrocycle area and their technology platform that is based on over 20 years of pioneering experience in small molecule macrocyclic chemistry," said David Warshawsky, Ph.D., Chief Executive Officer of Vuja De. "We are very pleased to work with Cyclenium on identifying and developing novel game-changing drug candidates that prevent metastatic recurrence, the most urgent need of most cancer patients," he added.